// App-Quantinova.ai

255 : Secukinumab provides rapid and sustained resolution of enthesitis in psoriatic arthritis patients: pooled analysis of two Phase 3 studies, FUTURE 2 and FUTURE 3

Researchers

Presenter

  • Laura C Coates

Principal Investigators

  • Dennis McGonagle

  • Georg Schett

  • Philip J Mease

  • Erhard Quebe-Fehling

  • Darren L Asquith

  • Lawrence Rasouliyan

  • Shepard Mpofu

  • Corine Gaillez

Medical Centers

  • Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

  • Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK

  • Department of Internal Medicine , Rheumatology & Immunology, University of Erlangen-Nuremberg, Erlangen, Germany

  • Department of Rheumatology, Swedish Medical Center and University of Washington, Seattle, WA

  • Global Medical Affairs Biostatistics in Global Drug Development, Novartis Pharma AG, Basel, SWITZERLAND

  • Rheumatology Immunology, Hepatology and Dermatology Franchise, Novartis Pharmaceuticals UK Ltd., Camberley, UNITED KINGDOM

  • Biostatistics, RTI Health Solutions, Barcelona, Spain,

  • Immunology, Hepatology, and Dermatology Development Unit, Novartis Pharma AG, Basel, SWITZERLAND

Locations

  • United Kingdom

  • Germany

  • United States

  • Switzerland

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • NCT01752634

  • NCT01989468

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved